Impact of intravitreal injection therapy on contrast sensitivity in patients with nAMD and DME
Open Access
- 9 January 2023
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 261 (7) , 1823-1833
Abstract
Purpose: The study aims to evaluate changes in contrast sensitivity (CS) during therapy with intravitreal vascular endothelial growth factor (VEGF) inhibitors in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Methods: Prospective, uncontrolled, multicenter study on patients with neovascular AMD or DME who underwent intravitreal injection therapy with Ranibizumab, Aflibercept, or Bevacizumab was conducted. Best corrected visual acuity (BCVA) and CS measured by Mars Letter Contrast Sensitivity Test (MLCS) and Freiburg Visual Acuity and Contrast Test (FrACT) in logCS were evaluated before 3 consecutive VEGF inhibitor injections, which followed the pro renata regimen in treatment-naïve and pretreated eyes with a maximum of 9 injections. Correlation of MLCS and FrACT was calculated by the Spearman’s rank correlation coefficient. Results: Eighty eyes of 74 patients (mean age 72.7; SD ± 9.96) were included. BCVA improved significantly from 0.44 (SD ± 0.21) logMAR to 0.38 (SD ± 0.23) logMAR by 0.06 (SD ± 0.14) logMAR values (p < 0.001). CS measured by MLCS increased significantly from 1.27 (SD ± 0.25) logCS to 1.39 (SD ± 0.22) logCS (p < 0.001). CS measured by FrACT also improved significantly from 1.22 (SD ± 0.32) logCS to 1.30 (SD ± 0.29) logCS (p = 0.035). A positive correlation between MLCS and FrACT was found (r = 0.389; p < 0.001). Despite statistical significance, results for BCVA, MLCS, and FrACT failed clinical significance. Overall best test results were achieved with MLCS. Conclusions: Intravitreal injection therapy with VEGF inhibitors led to an improvement of BCVA and CS measured by MLCS and FrACT. MLCS was superior and more sensitive compared to FrACT and even BCVA to evaluate CS in elderly patients with macular pathology.Keywords
Funding Information
- Charité - Universitätsmedizin Berlin
This publication has 38 references indexed in Scilit:
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2011
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study)Diabetes Care, 2010
- Effects of Retinal Morphology on Contrast Sensitivity and Reading Ability in Neovascular Age-Related Macular DegenerationInvestigative Ophthalmology & Visual Science, 2010
- Clinical assessment of two new contrast sensitivity chartsBritish Journal of Ophthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Improving the Design of the Letter Contrast Sensitivity TestInvestigative Ophthalmology & Visual Science, 2005
- Contrast sensitivity as an outcome measure in patients with subfoveal choroidal neovascularisation due to age-related macular degenerationEye, 2004
- Sehschärfebestimmung nach Europäischer Norm: wissenschaftliche Grundlagen und Möglichkeiten der automatischen MessungKlinische Monatsblätter für Augenheilkunde, 1998